Beactica Therapeutics initiates IND-enabling studies for BEA-17, a first-in-class LSD1-CoREST degrader for glioblastoma ...Middle East

UPPSALA, Sweden, Sept. 22, 2026 /PRNewswire/ -- Beactica Therapeutics AB, a Swedish precision medicine company, today announced the initiation of IND-enabling studies for BEA-17, the Company's wholly owned, first-in-class oral degrader of the epigenetic regulators LSD1 and CoREST, being...

Hence then, the article about beactica therapeutics initiates ind enabling studies for bea 17 a first in class lsd1 corest degrader for glioblastoma was published today ( Tuesday 22/09/2026 - 09:26 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Beactica Therapeutics initiates IND-enabling studies for BEA-17, a first-in-class LSD1-CoREST degrader for glioblastoma )

Also on site :

• Meta May Try to Repair Its Poor Privacy Reputation at 'Connect 2026'
• ‘Forgotten Island’ Review: H.E.R. And Dave Franco Give Life To Gorgeously Animated And Frenetic ‘Toon
• Princess Diana’s Brother Reveals What Bombshell Claims About King Charles Won’t ‘Be a Surprise’ to William & Harry